{
    "id": 5536,
    "fullName": "MDM2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MDM2 over exp indicates an over expression of the Mdm2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4193,
        "geneSymbol": "MDM2",
        "terms": [
            "MDM2",
            "ACTFS",
            "hdm2",
            "HDMX",
            "LSKB"
        ]
    },
    "variant": "over exp",
    "createDate": "04/29/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line over expressing MDM2 and wild-type for TP53 demonstrated sensitivity to treatment with MX69 in culture, resulting in decreased cell survival (PMID: 27666947).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4775,
                "therapyName": "MX69",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6705,
                    "pubMedId": 27666947,
                    "title": "Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27666947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8625,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MX69 treatment induced cell death and inhibited cell growth in a TP53 wild-type acute lymphocytic leukemia cell line over expressing MDM2, and prolonged survival in xenograft models (PMID: 27666947).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4775,
                "therapyName": "MX69",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6705,
                    "pubMedId": 27666947,
                    "title": "Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27666947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9314,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type, MDM2 over-expressing osteosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2155,
                "therapyName": "RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13088,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AQ-101 inhibited growth and induced apoptosis in acute lymphocytic leukemia (ALL) cell lines with wild-type TP53 and overexpression of MDM2 in culture, and inhibited development of leukemia in ALL cell line xenograft models (PMID: 29282301).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 6682,
                "therapyName": "AQ-101",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10752,
                    "pubMedId": 29282301,
                    "title": "Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29282301"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20274,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of MA242 restored sensitivity to Gemzar (gemcitabine) in Nfact2-positive and Mdm2-overexpressing pancreatic cancer cell lines, resulted in increased apoptosis in culture and complete tumor regression and inhibition of metastasis in orthotopic cell line xenograft models (PMID: 30217928).",
            "molecularProfile": {
                "id": 34998,
                "profileName": "MDM2 over exp NFATC2 pos"
            },
            "therapy": {
                "id": 9308,
                "therapyName": "Gemcitabine + MA242",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17789,
                    "pubMedId": 30217928,
                    "title": "Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30217928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MA242 induced cell cycle arrest and apoptosis in Nfatc2-positive and Mdm2-overexpressing pancreatic cancer cell lines in culture regardless of their Tp53 status, and inhibited tumor growth and metastasis in orthotopic cell line xenograft models (PMID: 30217928).",
            "molecularProfile": {
                "id": 34998,
                "profileName": "MDM2 over exp NFATC2 pos"
            },
            "therapy": {
                "id": 9307,
                "therapyName": "MA242",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17789,
                    "pubMedId": 30217928,
                    "title": "Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30217928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5357,
            "profileName": "MDM2 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4225,
                    "name": "MDM2 Inhibitor",
                    "profileName": "MDM2 over exp"
                }
            ]
        },
        {
            "id": 26380,
            "profileName": "MDM2 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34998,
            "profileName": "MDM2 over exp NFATC2 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}